Stock Ratings / Health Care / TGTX / options

PTGX (65) MDGL (38) CORT (63) CYTK (28) ⌘ Pro Terminal →

TG Therapeutics Inc. (TGTX) Options Positioning, Max Pain & Unusual Sweeps

$61.18 +5.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $61.65

TG Therapeutics Inc. (TGTX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $9.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TGTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, TG Therapeutics Inc. (NASDAQ: TGTX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $61.18 (+5.34% 1D, market cap $9.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TGTX ranks #136 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TGTX compare to PTGX and MDGL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TGTX carries a Roarable C (63/100 RQD), trailing P/E of 19.9x, gross margin of 83.7%, and ROIC of 12.0%. By comparison, PTGX (Protagonist Therapeutics Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TGTX?

▼

Per TGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001001316), TG Therapeutics Inc. generated $616.3M in revenue (+87.3% YoY), $447.2M in net income, and -$25.0M in free cash flow against $1.06B in total assets and $245.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $61.65 (+0.77%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TGTX)Realized 20D OHLCV Swing Band: ±8.4%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY TGTX SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (29% of score)

20D Institutional Volume Accumulation (±8.4% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 12.92 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$54.37-2.2% Next Q

Q2 (-2Q)

Grade C$53.20+7.9% Next Q

Q3 (-1Q)

Grade C$57.40+6.6% Next Q

Current

Grade C$61.18+0.9% Hist 90D α

Trajectory: C (55) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TGTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, TGTX faces multiple-compression risk if 19.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.80% YoY Shares) — any gross margin slip below 81.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($55.56) or 200D SMA ($44.23) invalidates the momentum regime and cuts Target Base ($62.56) toward Bear Floor ($48.80).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TGTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TGTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.4%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (TGTX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for TGTX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating TGTX & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on TGTX
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.32%⚡ TESTING RESISTANCE

2026-11-03O $58.08H $61.18L $58.08C $61.18VOL 2.86M

RES: $62.01SUP: $52.74SMA50: $55.56SMA200: $44.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TGTX Butterfly Map → + Track TGTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

13.4%/yr Implied 5Y Growth

vs. +87.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TGTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TGTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TGTX)

Health Care Rank #136 of 1016 ⚔️ PTGX vs TGTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TGTX vs. PTGX, MDGL, CORT, CYTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TG Therapeutics Inc. (TGTX) ranks #136 by composite RQD confidence (63/100, grade C) and #119 by equity capitalization ($9.36B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TGTX at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TGTX ACTIVE TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	+5.34%	$9.36B	Benchmark Subject
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	+0.35%	$9.37B	/ptgx-vs-tgtx →
MDGL Madrigal Pharmaceuticals Inc.	D-	38/100	—	—	-29.7%	-0.31%	$9.94B	/mdgl-vs-tgtx →
CORT Corcept Therapeutics Incorporated	C	63/100	93.2x	96.0%	4.8%	-5.62%	$8.77B	/cort-vs-tgtx →
CYTK Cytokinetics Incorporated	E	28/100	—	—	-35.0%	-0.50%	$8.76B	/cytk-vs-tgtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001001316

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TG Therapeutics Inc. (TGTX) reported GAAP revenue of $616.3M (+87.3% vs. FY2024 revenue of $329.0M , and +163.8% cumulative change since FY2023) , GAAP net income of $447.2M, operating cash flow of -$24.8M, and free cash flow of -$25.0M (+38.4% YoY). On the balance sheet, TGTX closed FY2025 with $1.06B in total assets against $245.6M in total debt (Altman Z-Score: 12.92, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$616.3M	$447.2M	-$24.8M	-$25.0M	$1.06B	$245.6M
FY2024 (FY)	2024-12-31	$329.0M	$23.4M	-$40.5M	-$40.6M	$577.7M	$244.4M
FY2023 (FY)	2023-12-31	$233.7M	$12.7M	-$31.4M	-$41.9M	$4.89B	$1.14B

3. TGTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TGTX compare to PTGX and MDGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TGTX?

Where is TGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

TGTX last traded at $61.18 (+5.34% on volume of 2,856,258 shares), positioning the stock +10.12% above its 50-day simple moving average ($55.56) and +38.32% above its 200-day simple moving average ($44.23). Across its 52-week range of $26.76 to $61.76, TGTX sits at the 98.3% percentile with a 14-day RSI of 64.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.4% ($56.04 to $66.32).

TGTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is TGTX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TGTX.

Direct Sub-Reports: TGTX RQD Cockpit TGTX 12M Forecast TGTX Earnings & Move TGTX Dividends & DRIP TGTX Insiders & 13F TGTX Whale Options TGTX Profit Sankey TGTX News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TGTX — TG Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:17:16Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TGTX scores 62 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." Across the five pillars, the Fundamental Cash Engine scores 9 of 20, reflecting an ROIC of 12% and an FCF yield of -0.28%. The Whale 13F Flow pillar scores 17 of 20, indicating institutional accumulation and options positioning as the rating's strongest component. Insider Conviction scores 9 of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 11 of 20, with a beta of 0.87 and sector sensitivity noted. Forensic Balance Sheet scores 16 of 20, supported by an Altman Z-Score of 12.92, a Piotroski F-Score of 6 of 9, and a Debt/Equity ratio of 0.38.

For a prospective investor, the profile is mixed. Institutional positioning is the primary upside driver in the rating, and the balance sheet forensics are comparatively strong. Cash-generation quality and insider conviction are the weaker pillars, and the negative FCF yield means the current valuation is not supported by free cash flow in the source data. The EV/EBITDA of 73.3 against a forward P/E of 16.7 illustrates a valuation tradeoff: earnings-based multiples look moderate while enterprise-value-based multiples look elevated. The rating's "Hold" label reflects this balance rather than a directional call. This is educational context, not personalized advice.

Snapshot

Metric	Value
Price	58.08
Market Cap	$8.89B
P/E (TTM)	19.9
Forward P/E	16.7
EV/EBITDA	73.3
EPS (TTM)	2.92
Dividend Yield	0%
Beta	0.87
52-Wk Range	$26.76 - $61.76
ROIC %	12%

Business

TG Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile identifies a market capitalization of $8.9B. Source data does not describe its specific products, customers, or revenue model beyond the sector and industry classification. Recent news items reference multiple sclerosis clinical data presented at MSToronto2026, per the Recent Catalysts section.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$616.3M	$123.3M	$447.2M	N/A	$-25.0M	$79.1M	$245.6M
FY 2024	$329.0M	$41.9M	$23.4M	N/A	$-40.6M	$179.9M	$244.4M
FY 2023	$233.7M	$20.6M	$12.7M	N/A	$-41.9M	N/A	$1144.2M

Per the SEC financials, revenue rose from $233.7M in FY 2023 to $616.3M in FY 2025. Net income in FY 2025 ($447.2M) substantially exceeds operating income ($123.3M), a gap the source data does not explain. Market data reports a gross margin of 83.7%, an operating margin of 20%, and a net margin of 68%. The Altman Z-Score is 12.92 and the Piotroski F-Score is 6 of 9, per the Roarable RQD rating. Reported FCF was negative in all three periods, and the balance sheet shows debt of $245.6M against cash of $79.1M at FY 2025.

Open Questions

What drives the gap between FY 2025 net income ($447.2M) and operating income ($123.3M), and is it recurring?
Why is FCF negative in every reported period despite revenue growth, and when might it turn positive?
What is the EV/EBITDA of 73.3 measuring relative to the forward P/E of 16.7, and what explains the divergence?
What products generate the reported revenue, and what is the exposure to the multiple sclerosis portfolio?
Who are the institutional holders and insiders behind the Whale 13F and Insider Conviction pillars?

TGTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TG Therapeutics Inc. (TGTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TGTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow

Yahoo Finance report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TG Therapeutics • 22h ago

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

TG Therapeutics report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 1d ago

TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech

ChartMill report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

TG Therapeutics Stock Climbs 15% On A 6-Day Winning Streak

Trefis report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

TradingView report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story

Yahoo Finance report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 1d ago

TG Therapeutics (NASDAQ:TGTX) Pairs Strong Growth With a High-Quality Breakout Setup

ChartMill report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Funds from operations of TG Therapeutics, Inc. – NASDAQ:TGTX

TradingView report covering TG Therapeutics Inc. (TGTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TGTX Bull vs. Bear Conversation Board — What's Your Call at $61.18?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TGTX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $62.73 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TGTX (C • RQD 62/100) a Buy at $58.08?

Welcome to the TGTX (TG Therapeutics Inc.) Roar Pit. Current RQD Composite is 62/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $45.88 (-21.0%)

Spot @ $58.08

Pump the brakes on TGTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TGTX, but look at what you are paying: 19.9x trailing P/E with 83.7% gross margins. Unless TG Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $66.21 (+14.0%)

Spot @ $58.08

TGTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TGTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $58.08 (52-wk range $26.76 - $61.76), any beat on forward guidance forces shorts and underweight funds to chase.